Professor Erik C. Böttger is Professor of Microbiology, Director and Chairman of the Institute of Medical Microbiology at Zurich University. He is a world renowned expert in antibacterial drug resistance, in vitro drug susceptibility testing and antibiotic compound development. He has authored some of the most influential and seminal papers in the field of antibacterial drug resistance and has over 200 peer-reviewed scientific articles on record. He has received numerous awards, including the prestigious Körber Award for European Science. He is ranked among the world’s most cited and influential microbiologists of the past two decades.
Professor David Crich is Schaap Professor of Chemistry at Wayne State University in Detroit, MI, USA. He graduated Docteur ès Sciences in organic chemistry from the Université de Paris Sud. After postdoctoral studies at the CNRS Institute de Chimie des Substances Naturelles (ICSN), he joined the faculty of University College London, UK, before moving to the University of Illinois at Chicago. He has also served recently as the Directeur (Head) of the ICSN. He has over thirty years of experience in organic and medicinal chemistry research, with particular emphasis on carbohydrate chemistry. David Crich has published around 350 peer-reviewed papers in the field of organic chemistry and has received numerous awards for his work.
Dr. Gunter Festel has a deep understanding of scientific and business aspects due to 20 years' experience in technology development and commercialisation of new technologies working for companies, like Bayer, McKinsey, Arthur D. Little and his own company Festel Capital. He has co-founded 10 technology companies in Germany and Switzerland. For example, he was founder and CEO of TES Triton Environmental Solutions developing a waste water treatment technology originally coming from Evonik Industries, which was sold to Triton Water in Germany in 2009. He was also co-founder and CEO of Butalco developing a biotechnology platform for the production of biofuels and biochemicals, which was sold to the French company Lesaffre in 2014. Gunter Festel is currently chairman of the board of the Association of German Biotechnology Companies.
Dr. Sven Hobbie has been a principal scientist in the development of Juvabis’ proprietary technology platform. Sven holds a PhD of the ETH Zurich and has more than 15 years of hands-on research experience in microbiology and anti-invective drug discovery, with positions held at the Michigan State University, Universität Konstanz, Universität Zürich, the Massachusetts Institute of Technology, and Visterra Inc. Sven’s track record in applied and translational sciences includes both biologics and small molecule therapeutics and is reflected in various research publications, invention disclosures, patents, an MIT Innovation Grant, a PhD award, and an invitation to join the Duke-NUS Medical School as Adjunct Assistant Professor. Sven has contributed to establishing an MIT research institute in Singapore and successfully spinning out the antiviral drug discovery company Visterra Singapore.
Professor Andrea Vasella is retired Professor of Swiss Federal Institute of Technology Zurich. He obtained his PhD from Swiss Federal Institute of Technology Zurich with distinction. After postdoctoral studies at King’s College, London, and Harvard University, he returned to Swiss Federal Institute of Technology Zurich, moved to the University of Fribourg, then to Zurich University, and finally back to the Swiss Federal Institute of Technology Zurich. He has over forty years of experience in organic and medicinal chemistry, and over thirty years as consultant of CROs, Pharma, and Agro Companies. He has published around 340 peer-reviewed papers and received several awards for his work.